相关实验视频
Updated: May 12, 2026

07:29
Programmed Electrical Stimulation in Mice
Published on: May 27, 2010
在SCN5A相关的心律失常综合征中,flekainide作用的关门依赖机制
P C Viswanathan1, C R Bezzina, A L George
1Department of Anesthesiology, Vanderbilt University, Nashville, Tennessee, USA.
Circulation
|September 6, 2001
概括
心脏通道 (SCN5A) 突变导致LQT3和布鲁加达综合征. 这些突变中的非激活门缺陷会增加对弗莱卡尼德的敏感性,可能导致危险的心律失常.
科学领域:
- 心血管遗传学 心血管遗传学
- 分子心脏病学分子心脏病学
- 电子生理学 电子生理学
背景情况:
- 心脏通道基因 (SCN5A) 的突变与LQT3和布鲁加达综合征有关.
- 针对通道的抗节律药物可以对这些情况产生相反的效果.
- 矛盾的是,弗莱卡尼德是一种通道阻塞剂,可以使布鲁加达综合征恶化,并在LQT3患者中引起类似的影响.
研究的目的:
- 研究LQT3和布鲁加达综合征中的SCN5A无活化门缺陷如何导致对弗莱卡因的前节律敏感性.
- 阐明这些遗传性心脏病中弗莱卡尼德诱导的心律失常的机制基础.
主要方法:
- 在表达LQT3 (DeltaKPQ) 和结合LQT3/布鲁加达 (1795insD) 突变的tsA-201细胞中测量了全细胞电流 (I(Na)).
- 评估了弗莱卡尼德 (1微摩尔/升) 对I(Na) 的影响和无活化后的恢复.
- 在突变型和野生型通道之间比较弗莱卡因尼德阻断和恢复动力学.
主要成果:
- 两种DeltaKPQ和1795insD突变都改变了无活化门,导致由flekainide强化增强性I(Na) 阻断.
- 与野生类型 (16.8%) 相比,弗莱凯尼德在1795insD (58.0%) 和DeltaKPQ (39.4%) 道中引起了显著更大的增强性阻塞.
- 1795insD突变还延迟了无活化后的恢复,表明增强了中间无活化和使用依赖的flekainide阻断.
结论:
- 确定了两个特定的失活关口缺陷 (封闭状态快速失活和中间失活) 作为对LQT3和布鲁加达综合征突变flecainide敏感性的关键因素.
- 这些发现为预测基于SCN5A突变类型的flekainide的前节律潜力提供了机制性的理由.
- 识别这些SCN5A无活化门缺陷可以帮助风险分层和个性化治疗策略,为这些通道病变的患者.
相关概念视频
Voltage-gated Ion Channels
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
G-Protein Gated Ion Channels
GPCRs are primarily responsible for our sense of smell, taste, and vision. The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Sensory organs,...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

